Skip to content

Study · Not a test of the peptide alone · 2014

1 result

Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures.

Fukuda F, Kurinomaru N, Hijioka A

Biologics in therapy29 Jan 2014Cited by 23 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome

    In a woman with delayed atypical femoral fracture union after fixation, bilateral union occurred after 3 months of weekly teriparatide.

    In plain wordsIn a woman with surgically fixed atypical femoral fractures, both fractures united after 3 months of weekly teriparatide.

    Outcome
    Not applicableBilateral femoral fracture union
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Union of bilateral femurs was achieved after 3 months of a once-weekly administration of TPTD.
    4 context sentences
    Summary · context
    The authors describe a case of AFFs successfully treated with once-weekly administration of 56.5 μg teriparatide (TPTD).
    Summary · context
    The patient was a 74-year-old female patient who had been taking alendronate for approximately 6 years and who suffered with a fall while walking.
    Summary · context
    The patient underwent osteosynthesis with intramedullary nailing for the right fracture.
    Summary · context
    Prophylactic osteosynthesis was performed for the subtrochanteric left femur.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.